Prognosis
BioNTech Raises Covid Vaccine Sales Forecast to $15 Billion
- Vaccine access expanding to new populations, CEO Sahin says
- mRNA shots have become mainstay of immunization drives
Photographer: Vincent Kalut/Getty Images
This article is for subscribers only.
BioNTech SE boosted its Covid-19 vaccine sales forecast to 12.4 billion euros ($15.1 billion) for this year, issuing a new target for the shot it sells with Pfizer Inc. as countries increase orders to spur their inoculation campaigns.
The partners have contracted for about 1.8 billion doses this year and started clinching deals for 2022 and beyond, the Mainz, Germany-based company said Monday. BioNTech had previously predicted 9.8 billion euros in 2021 revenue from the shot, its first marketed product.